Vima Therapeutics Extends Series A to USD 100 Million as Dystonia Phase 2 Trial Begins Dosing

Cambridge, Massachusetts-based Vima Therapeutics, a clinical-stage company developing oral therapies for movement disorders, has extended its Series A financing to USD 100 million with a new USD 40 million raise. The company simultaneously announced that the first patient has been dosed in a Phase 2 clinical trial of its lead candidate, VIM0423, in isolated dystonia. Vima Therapeutics dystonia and Parkinson's disease programs now have funding to advance through two Phase 2 studies, with topline data from both expected in H1 2027.

Frazier Life Sciences joined the round as a new investor, with Joe Cabral, a partner at the firm, taking a seat on Vima's board of directors. Existing investors Atlas Venture, Access Industries, and Canaan Partners also participated. The company said the financing will enable completion of two Phase 2 trials with VIM0423, one in isolated dystonia and one in Parkinson's disease. The Parkinson's disease trial is expected to initiate in mid-2026.

VIM0423 is described as a once-daily oral therapy designed to selectively target muscarinic cholinergic receptors in the brain. The compound addresses a dopamine-acetylcholine signaling imbalance that is implicated in both dystonia and Parkinson's disease, where excessive cholinergic activity through muscarinic receptors is thought to contribute to motor dysfunction. Anticholinergic drugs have long been used in movement disorders, but existing agents block muscarinic receptors non-selectively, causing peripheral and cognitive side effects that limit their clinical utility. VIM0423 has been designed to maximize selectivity for central nervous system targets. The compound has received Fast Track designation from the US FDA for the treatment of isolated dystonia, which affects more than 160,000 adults and children in the United States. The Phase 2 dystonia study, called Stride Dystonia, is now enrolling.

A completed two-part Phase 1 study evaluated pharmacokinetics, safety, tolerability, and dose titration in healthy volunteers and individuals with dystonia. Across single- and multiple-dose cohorts, VIM0423 was well-tolerated up to and above target doses over 28 days and achieved target exposure levels, the company said. Bernard Ravina, MD, MS, founder and chief executive officer of Vima, said the Phase 1 data "give us confidence that VIM0423 may address those needs for people living with movement disorders." Ravina, a neurologist, noted that dystonia and Parkinson's disease "share underlying disease biology driven by an imbalance in dopamine and acetylcholine signaling in the brain."

Vima holds an exclusive worldwide license from Children's Mercy, a pediatric health system in Kansas City, Missouri, to methods and compositions for treating movement disorders with certain antimuscarinic compounds. The company was founded and incubated at Atlas Venture by physicians and scientists with expertise in movement disorders. No additional pipeline candidates beyond VIM0423 have been disclosed. No prior out-licensing, co-development, or commercial partnership deals have been publicly announced by the company. The USD 100 million Series A, inclusive of this extension, represents the only disclosed funding round to date.

---

Spot something wrong? Report an issue with this article